Statin use and breast cancer risk in a large population-based setting

Denise M. Boudreau, Onchee Yu, Diana L Miglioretti, Diana S M Buist, Susan R. Heckbert, Janet R. Daling

Research output: Contribution to journalArticle

65 Citations (Scopus)

Abstract

Background: Mechanistic studies suggest that 3-hydroxy-3-methylglutaryl CoA inhibitors (statins) reduce the risk of breast cancer. Observational studies offer mixed results. Methods: To evaluate the relation between statin use and breast cancer risk, we conducted a cohort study among women ages 45 to 89 years within an integrated health care delivery system. Information on statin use and covariates were obtained from automated databases. We identified breast cancer cases through the Surveillance, Epidemiology, and End Results registry. We used Cox proportional hazards models to estimate the hazard ratios (HR) and 95% confidence intervals (95% CI) for invasive breast cancer among statin users compared with nonusers. Results: Among 92,788 women studied from 1990 to 2004, median follow-up time was 6.4 years, and 2,707 breast cancer cases were identified. During the study period, 7.4% of women used statins for at least 1 year, and the median duration of use was 3.1 years. We found no difference in breast cancer risk among statin users (HR, 1.07; 95% CI, 0.88-1.29) compared with nonusers. Risk of breast cancer did not differ by duration of use (1-2.9, 3-4.9, or ≥5 years) or hydrophobic statin use. We found a suggestive increased risk of breast cancer among statin users of ≥5 years (HR, 1.27; 95% CI, 0.89-1.81 for any statins and HR, 1.47; 95% CI, 0.89-2.44 for hydrophobic statins) and of estrogen receptor-negative tumors with increasing duration of statin use (1-2.9 years: HR, 1.33; 95% CI, 0.64-2.77; 3-4.9 years: HR, 1.68; 95% CI, 0.72-3.92; ≥5 years: HR, 1.81; 95% CI, 0.75-4.36). Conclusion: This study does not support an association between statin use and breast cancer risk.

Original languageEnglish (US)
Pages (from-to)416-421
Number of pages6
JournalCancer Epidemiology Biomarkers and Prevention
Volume16
Issue number3
DOIs
StatePublished - Mar 2007
Externally publishedYes

Fingerprint

Hydroxymethylglutaryl-CoA Reductase Inhibitors
Breast Neoplasms
Population
Confidence Intervals
Integrated Delivery of Health Care
Proportional Hazards Models
Estrogen Receptors
Observational Studies
Registries
Epidemiology
Cohort Studies

ASJC Scopus subject areas

  • Epidemiology
  • Oncology

Cite this

Statin use and breast cancer risk in a large population-based setting. / Boudreau, Denise M.; Yu, Onchee; Miglioretti, Diana L; Buist, Diana S M; Heckbert, Susan R.; Daling, Janet R.

In: Cancer Epidemiology Biomarkers and Prevention, Vol. 16, No. 3, 03.2007, p. 416-421.

Research output: Contribution to journalArticle

Boudreau, Denise M. ; Yu, Onchee ; Miglioretti, Diana L ; Buist, Diana S M ; Heckbert, Susan R. ; Daling, Janet R. / Statin use and breast cancer risk in a large population-based setting. In: Cancer Epidemiology Biomarkers and Prevention. 2007 ; Vol. 16, No. 3. pp. 416-421.
@article{3a1d2a81e73a421f95182c4b9ba281da,
title = "Statin use and breast cancer risk in a large population-based setting",
abstract = "Background: Mechanistic studies suggest that 3-hydroxy-3-methylglutaryl CoA inhibitors (statins) reduce the risk of breast cancer. Observational studies offer mixed results. Methods: To evaluate the relation between statin use and breast cancer risk, we conducted a cohort study among women ages 45 to 89 years within an integrated health care delivery system. Information on statin use and covariates were obtained from automated databases. We identified breast cancer cases through the Surveillance, Epidemiology, and End Results registry. We used Cox proportional hazards models to estimate the hazard ratios (HR) and 95{\%} confidence intervals (95{\%} CI) for invasive breast cancer among statin users compared with nonusers. Results: Among 92,788 women studied from 1990 to 2004, median follow-up time was 6.4 years, and 2,707 breast cancer cases were identified. During the study period, 7.4{\%} of women used statins for at least 1 year, and the median duration of use was 3.1 years. We found no difference in breast cancer risk among statin users (HR, 1.07; 95{\%} CI, 0.88-1.29) compared with nonusers. Risk of breast cancer did not differ by duration of use (1-2.9, 3-4.9, or ≥5 years) or hydrophobic statin use. We found a suggestive increased risk of breast cancer among statin users of ≥5 years (HR, 1.27; 95{\%} CI, 0.89-1.81 for any statins and HR, 1.47; 95{\%} CI, 0.89-2.44 for hydrophobic statins) and of estrogen receptor-negative tumors with increasing duration of statin use (1-2.9 years: HR, 1.33; 95{\%} CI, 0.64-2.77; 3-4.9 years: HR, 1.68; 95{\%} CI, 0.72-3.92; ≥5 years: HR, 1.81; 95{\%} CI, 0.75-4.36). Conclusion: This study does not support an association between statin use and breast cancer risk.",
author = "Boudreau, {Denise M.} and Onchee Yu and Miglioretti, {Diana L} and Buist, {Diana S M} and Heckbert, {Susan R.} and Daling, {Janet R.}",
year = "2007",
month = "3",
doi = "10.1158/1055-9965.EPI-06-0737",
language = "English (US)",
volume = "16",
pages = "416--421",
journal = "Cancer Epidemiology Biomarkers and Prevention",
issn = "1055-9965",
publisher = "American Association for Cancer Research Inc.",
number = "3",

}

TY - JOUR

T1 - Statin use and breast cancer risk in a large population-based setting

AU - Boudreau, Denise M.

AU - Yu, Onchee

AU - Miglioretti, Diana L

AU - Buist, Diana S M

AU - Heckbert, Susan R.

AU - Daling, Janet R.

PY - 2007/3

Y1 - 2007/3

N2 - Background: Mechanistic studies suggest that 3-hydroxy-3-methylglutaryl CoA inhibitors (statins) reduce the risk of breast cancer. Observational studies offer mixed results. Methods: To evaluate the relation between statin use and breast cancer risk, we conducted a cohort study among women ages 45 to 89 years within an integrated health care delivery system. Information on statin use and covariates were obtained from automated databases. We identified breast cancer cases through the Surveillance, Epidemiology, and End Results registry. We used Cox proportional hazards models to estimate the hazard ratios (HR) and 95% confidence intervals (95% CI) for invasive breast cancer among statin users compared with nonusers. Results: Among 92,788 women studied from 1990 to 2004, median follow-up time was 6.4 years, and 2,707 breast cancer cases were identified. During the study period, 7.4% of women used statins for at least 1 year, and the median duration of use was 3.1 years. We found no difference in breast cancer risk among statin users (HR, 1.07; 95% CI, 0.88-1.29) compared with nonusers. Risk of breast cancer did not differ by duration of use (1-2.9, 3-4.9, or ≥5 years) or hydrophobic statin use. We found a suggestive increased risk of breast cancer among statin users of ≥5 years (HR, 1.27; 95% CI, 0.89-1.81 for any statins and HR, 1.47; 95% CI, 0.89-2.44 for hydrophobic statins) and of estrogen receptor-negative tumors with increasing duration of statin use (1-2.9 years: HR, 1.33; 95% CI, 0.64-2.77; 3-4.9 years: HR, 1.68; 95% CI, 0.72-3.92; ≥5 years: HR, 1.81; 95% CI, 0.75-4.36). Conclusion: This study does not support an association between statin use and breast cancer risk.

AB - Background: Mechanistic studies suggest that 3-hydroxy-3-methylglutaryl CoA inhibitors (statins) reduce the risk of breast cancer. Observational studies offer mixed results. Methods: To evaluate the relation between statin use and breast cancer risk, we conducted a cohort study among women ages 45 to 89 years within an integrated health care delivery system. Information on statin use and covariates were obtained from automated databases. We identified breast cancer cases through the Surveillance, Epidemiology, and End Results registry. We used Cox proportional hazards models to estimate the hazard ratios (HR) and 95% confidence intervals (95% CI) for invasive breast cancer among statin users compared with nonusers. Results: Among 92,788 women studied from 1990 to 2004, median follow-up time was 6.4 years, and 2,707 breast cancer cases were identified. During the study period, 7.4% of women used statins for at least 1 year, and the median duration of use was 3.1 years. We found no difference in breast cancer risk among statin users (HR, 1.07; 95% CI, 0.88-1.29) compared with nonusers. Risk of breast cancer did not differ by duration of use (1-2.9, 3-4.9, or ≥5 years) or hydrophobic statin use. We found a suggestive increased risk of breast cancer among statin users of ≥5 years (HR, 1.27; 95% CI, 0.89-1.81 for any statins and HR, 1.47; 95% CI, 0.89-2.44 for hydrophobic statins) and of estrogen receptor-negative tumors with increasing duration of statin use (1-2.9 years: HR, 1.33; 95% CI, 0.64-2.77; 3-4.9 years: HR, 1.68; 95% CI, 0.72-3.92; ≥5 years: HR, 1.81; 95% CI, 0.75-4.36). Conclusion: This study does not support an association between statin use and breast cancer risk.

UR - http://www.scopus.com/inward/record.url?scp=34047253021&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34047253021&partnerID=8YFLogxK

U2 - 10.1158/1055-9965.EPI-06-0737

DO - 10.1158/1055-9965.EPI-06-0737

M3 - Article

C2 - 17372235

AN - SCOPUS:34047253021

VL - 16

SP - 416

EP - 421

JO - Cancer Epidemiology Biomarkers and Prevention

JF - Cancer Epidemiology Biomarkers and Prevention

SN - 1055-9965

IS - 3

ER -